SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the &#34;Company&#34; or &#34;VivoSim&#34;), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for

VIVS

VivoSim Provides Financial and Listing Compliance Update

VivoSim Regains Nasdaq Compliance and Outlines 500%+ FY2027 Revenue Growth

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the &amp;#34;Company&amp;#34; or &amp;#34;VivoSim&amp;#34;), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>VivoSim regained Nasdaq compliance following July events, including a $5.0 million milestone from Eli Lilly and a $1.0 million escrow release. It also closed a July financing that raised $4.0 million gross ($3.6 million net), boosting cash to about $10.1 million. The company reiterates 500%+ FY2027 revenue growth guidance driven by NAM-based contract research services.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nasdaq staff indicated VivoSim regained compliance with Rule 5550(b)(1). This improves liquidity.</li><li>Lilly paid a $5M milestone; $1M released from escrow. FXR sale tie-in noted.</li><li>July 17 financing: gross $4M; net $3.6M; warrants issued. Warrants issued.</li><li>Cash on hand ~$10.1M as of Aug 3, 2026. Liquidity strong.</li><li>Shares outstanding rose to 13.39M by Aug 3; warrants added about 9.9M shares.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>VivoSim Labs, Inc. (VIVS)</strong>: Regained Nasdaq compliance; cash position strengthened; reiterates 500%+ FY2027 revenue growth guidance.</li><li><strong>Eli Lilly and Company (LLY)</strong>: Paid $5.0M milestone and facilitated $1.0M escrow release related to FXR program sale; potential ongoing collaboration.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>VivoSim&#039;s regulatory/compliance update, capital raise, and strong growth guidance place it in Corporate Developments. The combination of improved liquidity and growth outlook is material for equity valuation in the NAMs-enabled biotech services space.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nasdaq compliance restored may unlock improved liquidity and capital access.</li><li>Eli Lilly milestone and escrow release boost near-term cash balance.</li><li>July financing adds ~$3.6M net; warrants may dilute near-term equity base.</li><li>FY2027 revenue growth guidance of 500%+ could drive multiple expansion.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Nasdaq notice regaining compliance with Rule 5550(b)(1) dated Aug 4, 2026.</li><li>Cash on hand approximately $10.1 million as of Aug 3, 2026.</li><li>Shares outstanding: 3,194,295 as of Jun 30, 2026; 13,390,789 as of Aug 3, 2026.</li><li>July 17, 2026 financing: gross $4.0M, net $3.6M; price $0.85; pre-funded plus common warrants.</li><li>Eli Lilly milestone: $5.0M; $1.0M released from escrow on July 22, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy VIVS on improved liquidity and strong 500%+ FY2027 growth guidance within 3–6 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">SAN DIEGO, Aug.  06, 2026  (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/VIVS">VIVS</a>) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’ equity of $2.5M.</p>  <p align="justify">Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14, 2026 (the "Form 10-K"), the Company received a $5.0 million milestone payment from Eli Lilly and Company, and $1.0 million of additional cash was released from escrow on July 22, 2026, both in connection with the Company’s previous sale of its FXR program to Eli Lilly and Company. The Company also completed a financing on July 17, 2026, issuing pre-funded warrants and common warrants at a combined purchase price of $0.85 per share of common stock underlying the pre-funded warrants and received gross proceeds of $4.0 million, with net proceeds of approximately $3.6 million. </p>  <p align="justify">The Company is drawing attention to these events because the timing of the events means they were not reflected in the Company’s audited financial statements for the year ended March 31, 2026 included in Form 10-K and will not be in the financial statements in the Company’s upcoming Quarterly Report on Form 10-Q filing for the period ended June 30, 2026.</p>  <p align="justify">As of August 3, 2026, the Company’s cash on hand was approximately $10.1 million. Due to the significant events described above that occurred in July after the close of both the last fiscal year, the year ended March 31, 2026 and the first quarter of this fiscal year 2027, the quarter ending June 30, 2026, the Company is providing this additional information to investors in order to complement the financial statements previously included in the Company’s annual and quarterly filings with the SEC in order to provide stockholders and the public with updated information.</p>  <p align="justify">As of June 30, 2026, the Company had 3,194,295 shares of common stock outstanding, and as of August 3, 2026, the Company had 13,390,789 shares of common stock outstanding, which reflects 9,896,718 shares of common stock issued between July 15, 2026 and July 31, 2026 upon exercise of certain warrants to purchase common stock.</p>  <p align="justify">The Company reiterates its previously announced guidance that it anticipates 500%+ revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical companies.</p>  <p><strong>Preliminary Financial Information</strong></p>  <p align="justify">The unaudited financial information presented in this press release is preliminary and may change. The Company undertakes no obligation to update or supplement the information provided in this press release. The preliminary financial information included in this press release reflects the Company’s current estimates based on information available as of the date hereof and has been prepared by the Company’s management. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with the Generally Accepted Accounting Principles and is not necessarily indicative of the results to be achieved for any future periods. This preliminary financial information could be impacted by the effects of financial closing procedures, final adjustments and other developments.</p>  <p align="justify"><strong>About VivoSim Labs</strong></p>  <p align="justify">VivoSim Labs, Inc. ("VivoSim" and the "Company"), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.</p>  <p><strong>Forward-Looking Statements</strong></p>  <p align="justify"><em>Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. </em></p>  <p><strong>Contact(s):</strong><br></br>Investor Relations<br></br><u>info@vivosim.ai</u><br></br>VivoSim Labs, Inc.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNDgzMyM3NzYyMjY0IzIwMjAwODU="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MTFkNDY4MDQtZWM2MC00NzYwLWIwYTYtYTYwMmE2YzlkZDMxLTEwMzE2NTctMjAyNi0wOC0wNi1lbg==/tiny/VivoSim-Labs-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/636bff82-374b-4c96-8194-5345983eb76a"><img src="https://ml.globenewswire.com/media/636bff82-374b-4c96-8194-5345983eb76a/small/vivosim-logo-final-jpg.jpg" border="0" width="150" height="67" alt="Primary Logo"></img></a></p>

VivoSim regained Nasdaq compliance following July events, including a $5.0 million milestone from Eli Lilly and a $1.0 million escrow release. It also closed a July financing that raised $4.0 million gross ($3.6 million net), boosting cash to about $10.1 million. The company reiterates 500%+ FY2027 revenue growth guidance driven by NAM-based contract research services.

News insight

VivoSim Provides Financial and Listing Compliance Update

AI summary

Sentiment rationale

Key facts

Corporate Developments